Online inquiry

IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2026MR)

This product GTTS-WQ2026MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets INSR gene. The antibody can be applied in Hunter syndrome (MPS II) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000208.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3643
UniProt ID P06213
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2026MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7768MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GS-5745
GTTS-WQ9725MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ1095MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ3136MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ14425MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ3095MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ2450MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ4338MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW